23:19 , Nov 3, 2016 |  BC Week In Review  |  Company News

TetraLogic, Medivir deal

Medivir will acquire birinapant and suberohydroxamic acid phenyl ester (SHAPE) from TetraLogic for $12 million up front in cash; TetraLogic will subsequently delist from NASDAQ and terminate all remaining employees by Dec. 1. TetraLogic shareholders...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

None shall pass

Biotech recorded its worst quarter in about 14 years, and no market cap bands were spared from the carnage. Big caps, normally a safe haven during turbulent markets, shed 16.1% and had only three of...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Birinapant: Phase II discontinued

TetraLogic said it will terminate a double-blind, international Phase II trial after an interim analysis of 62 evaluable azacitidine-naive patients with higher risk MDS showed that twice-weekly 13 mg/m 2 IV birinapant for 3 weeks...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Birinapant: Preliminary Phase IIa data

Preliminary data from 9 azacitidine-naive patients with higher risk MDS in a double-blind, placebo-controlled, international Phase IIa trial showed that twice-weekly 13 mg/m 2 IV birinapant for 3 weeks of a 4-week cycle plus azacitidine...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

Birinapant: Phase Ib/IIa halted

TetraLogic temporarily halted enrollment in a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV birinapant following observed cranial nerve palsies in 2 of the 7 patients in the first cohort receiving the 1.4 mg/m 2...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

TetraLogic, Merck deal

TetraLogic and Merck will jointly conduct a Phase I trial evaluating TetraLogic’s birinapant in combination with Merck’s Keytruda pembrolizumab to treat relapsed or refractory solid tumors. TetraLogic will fund the study, and Merck will provide...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

Birinapant: Preliminary Phase Ib/IIa data

Preliminary data from 9 evaluable MDS patients in the dose-escalation Phase Ib portion of the open-label, U.S. Phase Ib/IIa TL32711-0087 trial showed that birinapant plus azacitidine led to a bone marrow blast count reduction from...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

TetraLogic, Walter and Eliza Hall Institute of Medical Research deal

The institute and TetraLogic partnered to develop birinapant to treat viral infections. The institute granted TetraLogic an exclusive, worldwide license to a patent application related to a method of treating intracellular infections involving the administration...
02:57 , Dec 13, 2013 |  BC Extra  |  Financial News

TetraLogic raises $50.1 million in IPO

Cancer company TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG) raised $50.1 million in an IPO through the sale of 7.2 million shares at $7, which values TetraLogic at $147.8 million. On Tuesday, the company had amended the offering...
02:45 , Dec 11, 2013 |  BC Extra  |  Financial News

TetraLogic drops proposed price for IPO

Cancer company TetraLogic Pharmaceuticals Corp. (Malvern, Pa.) amended its IPO and said it now plans to sell 6.5 million shares at $7. At the $7 price, the company would raise $45.5 million and be valued...